Multiple sclerosis: open trials in Canada

21 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT06782490
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Trial Treatment · Phase 2 · Celgene
University of Alberta Hospital, Edmonton · Centre de Recherche Saint-Louis, Lévis · University Hospital - London Health Sciences Centre, London · Montreal Neurological Institute and Hospital, Montreal · The Ottawa Hospital - General Campus, Ottawa · Unity Health Toronto, St. Michael's Hospital, Toronto
Registry updated 2026-10-27
NCT06846281
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Novartis Investigative Site, Edmonton · Novartis Investigative Site, Lévis · Novartis Investigative Site, Montreal · Novartis Investigative Site, Vancouver
Registry updated 2026-10-26
NCT07159789
Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
Trial Treatment · Clinique Neuro-Outaouais
Clinique Neuro-Outaouais, Gatineau
Registry updated 2026-10-22
NCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Trial Treatment · Phase 1 · Kite, A Gilead Company
Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal · Jewish General Hospital, Montreal · The Ottawa Hospital - General Campus, Ottawa
Registry updated 2026-10-19
NCT07875309
An Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online
Trial Treatment · University of Melbourne
MS Barlo Centre, St Michael's Hospital, Toronto
Registry updated 2026-10-15
NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Novartis Investigative Site, Burnaby · Novartis Investigative Site, Calgary · Novartis Investigative Site, Edmonton · Novartis Investigative Site, Halifax · Novartis Investigative Site, Lévis · Novartis Investigative Site, Montreal · Novartis Investigative Site, Ottawa · Novartis Investigative Site, Québec · Novartis Investigative Site, Sherbrooke · Novartis Investigative Site, Vancouver
Registry updated 2026-10-13
NCT03816345
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Trial Treatment · Phase 1 · National Cancer Institute (NCI)
University Health Network, Princess Margaret Hospital, Toronto
Registry updated 2026-10-05
NCT06261489
Cannabis (THC vs. CBD) in Multiple Sclerosis
Trial Treatment · Phase 2 · University of Calgary
University of Calgary Foothills Medical Center, Calgary · University Of Calgary, Calgary
Registry updated 2026-09-15
NCT07224373
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Trial Treatment · Phase 1 · AstraZeneca
Research Site, Montreal
Registry updated 2026-08-25
NCT06733922
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Novartis Investigative Site, Burnaby · Novartis Investigative Site, Calgary · Novartis Investigative Site, Edmonton · Novartis Investigative Site, Halifax · Novartis Investigative Site, Montreal · Novartis Investigative Site, Ottawa · Novartis Investigative Site, Québec · Novartis Investigative Site, Sherbrooke · Novartis Investigative Site, St. John's · Novartis Investigative Site, Vancouver
Registry updated 2026-05-15
NCT07562074
Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis
Trial Treatment · Phase 1 · University of Calgary
Foothills Medical Centre, Calgary
Registry updated 2026-05-01
NCT05061953
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
Research · Innodem Neurosciences
The Neuro, Montreal · Genge Partners Inc., Montreal
Registry updated 2026-04-01
NCT07174973
Innovative Approaches to Enhance Balance and Neuroplasticity in Multiple Sclerosis
Trial Treatment · University Health Network, Toronto
Toronto Rehabilitation Institute-Lyndhurst Center, Toronto
Registry updated 2026-03-16
NCT05347875
Implementation of an App-based Walking Aid Skills Training Program
Trial Treatment · University of Calgary
Foothills Medical Centre, Calgary · CIRRIS, Québec
Registry updated 2026-03-09
NCT04121468
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
Trial Treatment · Phase 1/2 · The Hospital for Sick Children
The Hospital for Sick Children, Toronto
Registry updated 2025-09-23
NCT07097402
Examination of a Self-Compassion Course for Healthcare Providers Working With People With Multiple Sclerosis
Trial Treatment · Robert Simpson
Unity Health Toronto, Toronto
Registry updated 2025-07-31
NCT05092191
Cannabis as a Complementary Treatment in Multiple Sclerosis
Trial Treatment · Phase 2 · Centre hospitalier de l'Université de Montréal (CHUM)
CRCHUM, Montreal
Registry updated 2024-12-13
NCT05451251
Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion
Trial Treatment · Phase 1 · Université de Sherbrooke
Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke
Registry updated 2024-12-12
NCT06415552
Implementation of Online Mindfulness-Based Stress Reduction Tailored for People with Multiple Sclerosis
Trial Treatment · Robert Simpson
St. Michael's Hospital, Toronto
Registry updated 2024-12-06
NCT06461741
EMG Biofeedback Training to Improve Balance in Individuals with Multiple Sclerosis
Trial Treatment · McMaster University
McMaster University, Hamilton
Registry updated 2024-12-03
NCT06171334
Remote Ischemic Conditioning in PPMS
Trial Treatment · University of Calgary
University Of Calgary, Calgary
Registry updated 2024-05-09

All Multiple sclerosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error